LabCorp Commences Offer for Orchid Shares | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has launched its cash tender offer to acquire all of the outstanding common shares of Orchid Cellmark.

The firms signed the merger agreement earlier this month, under which LabCorp will pay $2.80 per share to acquire all outstanding shares of Orchid including options. The total value of the deal is around $85.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.